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The salient feature of those living with chronic cardiovascular disease (CVD) is poor exercise 23	  
tolerance, the criterion measure of which is aerobic capacity (V̇O2peak). V̇O2peak reflects the 24	  
integrated capacity of the pulmonary, cardiovascular and neuromuscular systems to 25	  
transport and utilise O2, and is strongly correlated with health-related quality of life, predictive 26	  
of cardiac-related hospitalisations and is the most powerful predictor of prognosis.                                                                                                                         27	  
Indeed with every 1 ml·min-1·kg-1 reduction in V̇O2peak there is an increase in all-cause 28	  
mortality risk of ~16 % in both chronic heart failure (CHF)1 and coronary heart disease 29	  
(CHD).2 In addition, poor exercise tolerance in CVD propagates a downward spiral of further 30	  
inactivity and decreases in V̇O2peak that reduce functional capacity, with this underpinning 31	  
poor quality of life, increasing risk of death and the requirement for greater clinical support 32	  
and intervention.  33	  
 34	  
Exercise is one of nature’s great panaceas, which in the context of rehabilitation programs 35	  
can effectively improve function in a range of biological systems, conveying morbidity and 36	  
mortality protection, reducing hospitalizations and increasing quality of life in those living with 37	  
CVD. Thus, intervening with supervised exercise-based cardiac rehabilitation to slow, 38	  
prevent or even reverse the downward spiral in functional capacity anticipated with the 39	  
progression of CVD would be expected to convey a plethora of patient benefits that also 40	  
reduce the clinical burden. Indeed, exercise-based cardiac rehabilitation can promote 41	  
physiologic adaptations at all levels of the O2 delivery and utilization cascade; for example 42	  
reversing left ventricular remodeling to improve cardiac structure and function, and 43	  
increasing both endothelial and skeletal muscle function.3 While the specific mechanism and 44	  
magnitude of effect that underpins any associated change in V̇O2peak and functional capacity 45	  
will be dependent on CVD etiology and severity, in HF-ACTION – a large randomized 46	  
multicenter clinical trial in CHF patients – even a modest increase in V̇O2peak (i.e. 0.6 ml·min-47	  
1·kg-1; 6 %) reduced the risk of all-cause and cardiovascular mortality and hospitalizations 48	  
(Hazard ratios (HR) ranging from 0.92–0.95; 4–8 % reduction).4 Similarly, a recent Cochrane 49	  
review reported exercise-based cardiac rehabilitation to reduce cardiovascular mortality (HR 50	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0.74; 95% CI 0.64-0.86) and risk of hospitalization (HR 0.82; 95% CI 0.70-0.96) in those with 51	  
CHD.5   52	  
 53	  
Debate still surrounds the optimal protocol of exercise-based cardiac rehabilitation. For 54	  
example, several small, single-center studies have advocated the use of ‘high-intensity’ 55	  
interval training (HIIT) in cardiac rehabilitation, which utilizes 3-4 bouts of 3-4 min exercise at 56	  
85-90 % V̇O2peak interspersed with periods of recovery. Compared with standard moderate-57	  
intensity continuous exercise at 50-60 % V̇O2peak, HIIT promotes superior physiologic 58	  
cardiac, vascular and skeletal muscle adaptations that presumably underpin greater 59	  
increases in V̇O2peak (e.g. 14 vs. 46 % increase in V̇O2peak for standard vs. HIIT training).6 60	  
However, the outcome of larger scale, multicenter trials assessing the effectiveness of HIIT 61	  
on clinically relevant outcomes and safety remain outstanding.7 Thus, many issues remain to 62	  
be resolved in order to maximize the effectiveness of exercise-based cardiac rehabilitation, 63	  
with the impact of variables such as protocol (e.g. continuous vs. interval exercise) and 64	  
exercise intensity on safety, adherence and clinical outcomes key considerations. These 65	  
issues notwithstanding, there is a large body of evidence that justifies the inclusion of 66	  
supervised exercise-based cardiac rehabilitation in the UK National Institute for Health and 67	  
Care Excellence (NICE) CVD management pathway.8 68	  
 69	  
Conversely, supervised exercise-based ‘cardiac’ rehabilitation is noticeably absent from the 70	  
type 2 diabetes mellitus (T2DM) NICE management pathway.8 Although T2DM is a chronic 71	  
metabolic disease, the risk of developing CVD in those with T2DM is more than twice that of 72	  
the general population.9 In addition, the primary cause of death in those with T2DM is 73	  
CVD.10 Furthermore, patients with T2DM and CVD experience greater morbidity [for 74	  
example T2DM patients with concomitant CHF (CHF-T2DM) have worse CHF symptoms, 75	  
and have a greater requirement for diuretics despite better cardiac function],11 and 76	  
cardiovascular mortality (~ 50% greater risk of death in both CHF-T2DM patients,11 and 77	  
T2DM patients who have had an acute myocardial infarction).12 These adverse CVD 78	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outcomes are of particular relevance given that it is predicted the global prevalence of T2DM 79	  
will be 1 in 10 people (642 million) by 2040.13 80	  
 81	  
A key mediator of the adverse CVD risk, increasing morbidity and mortality in T2DM, is the 82	  
(metabolic) consequences of obesity and insulin resistance. These promote a pro-83	  
inflammatory, pro-atherosclerotic environment that detrimentally impacts endothelial function 84	  
and underpins the vascular dysfunction that is common to both CVD and T2DM. Even in the 85	  
absence of a CVD diagnosis there is evidence of cardiovascular dysfunction in T2DM. While 86	  
pharmaceutical treatments are the mainstay intervention in T2DM, in the context of this 87	  
commentary, as highlighted in Brozic et al.14 it is significant that structured exercise-based 88	  
‘cardiac’ rehabilitation programs in T2DM reduce CVD risk by promoting physiologic 89	  
increases in vascular function (e.g. flow-mediated dilatation, arterial stiffness), can reduce 90	  
blood pressure and have positive effects on the blood lipid profile.15 This reduction in CVD 91	  
risk with structured exercise-based rehabilitation programs in T2DM is in addition to the 92	  
improvement in glycaemic control that provides clinically meaningful reductions in HbA1c 93	  
that can reduce the reliance on pharmaceutical intervention, and can be achieved in the 94	  
absence of weight loss or dietary intervention.16 Given the highlighted dual-benefits of 95	  
supervised exercise-based rehabilitation programs on both the metabolic and cardiovascular 96	  
risk aspects of T2DM it is unclear why these programs are not common place, and not part 97	  
of the NICE T2DM management pathway. Instead, pharmaceutical interventions to manage 98	  
hypertension, dyslipidemia and blood glucose are at the core of treatment, with no strategy 99	  
to arrest, attenuate or attempt to reverse the anticipated decline in functional capacity that is 100	  
an underlying driver for disease progression. 101	  
 102	  
In the setting of a T2DM epidemic, given the adverse cardiovascular consequences with 103	  
respect to CVD risk, morbidity and mortality, it would seem germane to (re)consider the 104	  
inclusion of a structured, supervised exercise-based ‘cardiac’ rehabilitation program in the 105	  
clinical management of T2DM to retard the progression of this disease. In the context of the 106	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inflated risk of developing CVD in T2DM, evident even at the pre-diabetic stage, it is striking 107	  
that CHF patients with concomitant T2DM (reflecting up to 50% of the heart failure 108	  
population), despite better cardiac function, have worse functional capacity (NYHA score) 109	  
than those without this co-morbidity.11 Similarly, CHF-T2DM patients have a lower V̇O2peak 110	  
than CHF patients, and have an attenuated physiologic response to exercise-based cardiac 111	  
rehabilitation: in HF-ACTION although the increase in V̇O2peak was significant in all patients, 112	  
this was smaller in CHF-T2DM than in CHF patients without concomitant T2DM (0.5 ± 2.4 113	  
vs. 0.9 ± 2.6 ml·min-1·kg-1), independent of reduced adherence.17 Worse pre-rehabilitation 114	  
status in CHF-T2DM raises the question of whether those with a primary diagnosis of T2DM 115	  
would gain long-term benefit from early participation in exercise-based cardiac rehabilitation, 116	  
prior to a CVD diagnosis and before functional capacity has declined to such an extreme 117	  
extent. The multi-faceted physiologic improvements achieved with exercise-based cardiac 118	  
rehabilitation means that, in addition to improving glycaemic control and reducing CVD risk, 119	  
the anticipated increase in functional capacity (V̇O2peak) might be expected to reduce the 120	  
adverse CVD morbidity and mortality risk in those with T2DM. Thus, intervening at an earlier 121	  
stage in the disease induced decline in functional capacity may promote long-term clinical 122	  
benefits in those with T2DM who develop overt CVD, and indeed in those who do not.  123	  
 124	  
An additional consideration that has proved difficult to resolve, is the optimal protocol of the 125	  
exercise rehabilitation. Combined resistance and aerobic exercise programs are more 126	  
effective than aerobic or resistance training in T2DM, promoting greater reductions in 127	  
HbA1c.18. It is possible that given the skeletal muscle and microvascular pathophysiologic 128	  
derangements of T2DM, the mainstay aerobic exercise cardiac rehabilitation program in 129	  
CVD is less effective than expected, and benefits limited by adverse skeletal muscle function 130	  
when T2DM exists as a co-morbidity. Thus, trials to identify the optimal exercise 131	  
rehabilitation program, and target this to the underpinning limitation to maximize physiologic 132	  
benefits are warranted. HIIT is an interesting prospect in this regard as this exercise strategy 133	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may allow different elements of the O2 delivery and utilization cascade to be targeted by 134	  
altering how the exercise is performed. For example, comprising an HIIT protocol of short 135	  
duration bouts of exercise at a high mechanical power may allow for greater skeletal muscle 136	  
and microvascular adaptations for a given cardiovascular strain than would be permitted 137	  
through standard aerobic ‘cardiac’ rehabilitation alone. This potentially provides an approach 138	  
that makes ‘aerobic’ HIIT rehabilitation analogous to combined resistance and aerobic 139	  
exercise rehabilitation to optimize the physiologic adaptations attained. However, the issue 140	  
of how to optimize the exercise rehabilitation program in T2DM, either in the presence or 141	  
absence of CVD remains unresolved.   142	  
 143	  
While theory and accompanying evidence-base supports the case for including supervised 144	  
exercise-based rehabilitation as a fundamental component of clinical management strategies 145	  
to alleviate the isolated or combined burden of CVD and T2DM, the elephant in the room 146	  
with regards implementing this in practice is adherence. While not widely acknowledged, a 147	  
self-selecting bias of physically active patients, or those ready for behavior change 148	  
volunteering and adhering to exercise rehabilitation studies may exist. However, inactivity is 149	  
a significant driver of the rising prevalence of both CVD and T2DM. Thus, those naïve to 150	  
regular exercise (with this potentially a root cause of their clinical status) may be less willing 151	  
or able to adhere to an exercise program. In the recent HF-ACTION study, adherence to 152	  
exercise was lower in CHF-T2DM (2.5 vs. 3.3 metabolic equivalent hr·wk-1 in those without 153	  
concurrent T2DM).17 The obvious connotation is that regardless of how effective exercise 154	  
interventions can be, exercise-based rehabilitation only works when the exercise program is 155	  
adhered to.  156	  
 157	  
Rehabilitation programs are therefore not just about identifying the optimal exercise strategy 158	  
to optimize physiologic adaptations in CVD and T2DM to reduce morbidity and mortality risk. 159	  
Exercise rehabilitation programs must also take account of how exercise can be prescribed 160	  
to account for differences in exercise preferences, increase enjoyment and support behavior 161	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change in a management scheme that promotes adherence to exercise-based rehabilitation. 162	  
Thus, although Brozic and colleagues14 highlight the clear potential of exercise-based 163	  
cardiac rehabilitation to attenuate CVD risk in T2DM, and advocate access to such programs 164	  
in clinical management, it is prudent to emphasize that exercise-based cardiac rehabilitation 165	  
is likely to be most effective when this is embedded as part of a multidisciplinary strategy 166	  
that balances approaches to optimize physiologic adaptations with tactics to improve 167	  
adherence.  168	  
 169	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